BNTX
BioNTech SECNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Positive late-stage oncology readouts and clear partnership/licensing deals for next-gen mRNA assets lead to rapid re-rating; commercial launches or label expansions accelerate revenue and justify premium multiples.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -4.0.
What can break
Clinical/regulatory setbacks for oncology programs
Momentum
24
Value
52
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $115.00 · Bull $160.00 · Bear $75.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-15 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $121.43
Why
Momentum24 · Δ7d +16.6
Value52 · Δ7d -0.1
Sentiment73 · Δ7d -4.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
24
26% active weight
Current posture
7d trendImproving
Δ7d
+16.6
Δ21d
+20.4
Value
52
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.3
Sentiment
73
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.0
Δ21d
-1.2
Why this grade
Composite grade C. Momentum 24.5 / Value 51.8 / Sentiment 72.5
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$23.13B
Beta
1.49
Shares Out
252.88M
P/E (TTM) · Derived
-17.2
P/S (TTM)
6.30
P/FCF (TTM) · Derived
17.55
Rev YoY
-28.2%
EPS YoY
+35.1%
Gross Margin
+73.3%
Op Margin
-29.6%
Net Debt
-$17.12B
Current Ratio
8.80
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology